AstraZeneca to Begin Supplying COVID-19 Vaccine in September

AstraZeneca Plc. plans to make over 30 million doses available in the United kingdom as early as September.



AstraZeneca-Coronavirus-COVID-Vaccine

New Cambridge R&D Centre and Global HQ (Image: AstraZeneca Plc)

The University of Oxford and AstraZeneca Plc have begun recruiting over 10,000 subjects for advanced human trials of experimental COVID-19 vaccine. If everything goes as planned, the drug maker will make first deliveries starting September 1.

A smaller part of the COVID-19 vaccine trial will expand the age range of testing to children from 5 to 12 years old and adults 56 and older. The larger stage will test the coronavirus vaccine’s effectiveness in volunteers 18 and older.

Pharmaceutical companies across the globe are in a race against time to develop an effective COVID-19 vaccine. A lot of these manufacturers are doing it for no profit.

COVID-19 Vaccine Production

AstraZeneca recently got a boost in its efforts to get the vaccine tested and ready for use when the United States pledged $1.2 billion on Thursday.

Adult subjects for the trial will be randomly chosen to receive one or two doses of the Oxford candidate or a licensed vaccine against meningococcus for comparison.

Volunteers will be recruited across the United Kingdom and will record their reactions in a journal as well as attend follow-up visits. Some of the volunteers will also be given swabs for taking samples at home.

This COVID-19 vaccine is made from a weakened version of a common cold virus that’s genetically modified to make it unable to grow in the human body. Over 1,000 volunteers have already received the coronavirus vaccine during an early-stage trial that began in April.

AstraZeneca Plc. plans to make over 30 million doses available in the United Kingdom as early as September. Meanwhile, the United States could begin receiving the COVID-19 vaccine as early as October.

A challenge for all of humanity  

AstraZeneca will be producing coronavirus vaccine in more than one country. The pharmaceutical company thanked the US and UK governments for significant support to accelerate the development and production of the COVID vaccine.

The drugmaker is also in discussions with the Serum Institute of India and other potential partners to increase COVID-19 vaccine production.

AstraZeneca said it is capable of producing one billion doses of the COVID vaccine this year and next. The company will make “every effort we can deliver these doses at no profit while at the same time working on parallel supply chains to supply the world.”

AstraZeneca CEO Pascal Soriot described the global coronavirus pandemic as a “global tragedy” and a “challenge for all of humanity.”

 

Whether you want to stay up-to-date on the latest business news, read in-depth CEO interviews, or find new ideas on leadership, management and innovation, Industry Leaders Magazine is here to suit your needs and help you stay more informed.

Anna Domanska
Anna Domanska is an Industry Leaders Magazine author possessing wide-range of knowledge for Business News. She is an avid reader and writer of Business and CEO Magazines and a rigorous follower of Business Leaders.

Recent Posts

Bayer snaps up biotech firm Vividion Therapeutics for $2 billion

Bayer snaps up biotech firm Vividion Therapeutics for $2 billion

Bayer AG is in talks to buy Vividion Therapeutics in a roughly $2 billion deal, enforcing new IPO plans for Vividion.
1 hour ago
Auto Industry Leaders push EV plans to maintain leadership

Auto Industry Leaders push EV plans to maintain leadership

Auto Industry Leaders push EV plans ahead to raise new outcomes by 2030. Environmentalists also add to the bar by shaking things with vehicle emission rules by 2026.
4 hours ago
General Motors Q2 2021 Results Recap

General Motors Q2 2021 Results Recap

General Motors Q2 earnings and revenue missed Wall Street’s expectations even though the world’s leading automaker beat earnings projections.
1 day ago
UK casts doubt over Nvidia’s Arm acquisition over security risks

UK casts doubt over Nvidia’s Arm acquisition over security risks

UK considers blocking Nvidia’s Arm acquisition due to potential risks to national security. The $40 billion takeover faces similar fate in America, China and the European Union.
1 day ago
PepsiCo relinquishes control of Tropicana for $3.3 billion

PepsiCo relinquishes control of Tropicana for $3.3 billion

PepsiCo will sell Tropicana and other juice brands to a private equity firm in exchange for pre-tax proceeds of 3.3 billion dollars.
2 days ago
Sanofi bets big on mRNA future with Translate Bio acquisition offer

Sanofi bets big on mRNA future with Translate Bio acquisition offer

Sanofi’s CEO Paul Hudson is dead serious about mRNA technology and capabilities with a $3.2 billion acquisition offer to Translate Bio.
2 days ago